



SCOTTSDALE
HEALTHCARESM

Osborn Cancer Program

Annual Report – 2014

Table of Contents

Cancer Program Activities	3
Physician Cancer Committee Members	4
Non-Physician Cancer Committee Members	4
Cancer Conferences	4
Top Ten Analytic Cancer Incidence by Gender - Male	5
Top Ten Analytic Cancer Incidence by Gender - Female	5
Analytic Incidence by Age Group and Gender	5
Standard of Care Quality Measures of the Commission on Cancer	6
System-wide 2013 Primary Site Table	7
Shea 2012 Primary Site Table	9
Osborn 2012 Primary Site Table	11
Thompson Peak 2012 Primary Site Table	13

Community Outreach at Scottsdale Healthcare is very active. In 2014, cancer programs alone numbered 537 with 15,496 participants plus exposure to an additional 14,523 people at four large events (Parada Del Sol, Leukemia/Lymphoma Walk, Lung Walk, and Komen) for a total of 30,019 people.

Community Outreach Support Group Meetings Included:

- BRCATEERS (BRCA Positive Support Group)
- Women of Scottsdale
- West Valley Women
- Central Phoenix Women
- Cancer Support and Education Forum
- East Valley Women
- Network of Strength Breast Cancer Support Group
- Pancreatic Support Group
- Diabetes Support Group
- Facing Forward Women's Support Group
- AZ Myeloma Network Caregiver Education Support Program

Community Outreach Events:

- Parada Del Sol Parade
- Parada Del Sol Rodeo
- Susan G. Komen Walk
- American Cancer Society Breakfast
- Pancreatic Community Event
- Social Work Luncheon
- Lymphoma Walk Breakfast
- Annual stepNout Run Walk
- Phoenix Symphony Trio – Healing Power of Music

- Cervical and Gynecological Cancer Event
- Making Strides Against Cancer
- Celebration of Life Leukemia / Lymphoma Walk
- LPGA Charity Pro-Am
- Interfaith Breakfast
- My Hope Bag – Breast Health Event
- Gift of Life Lodging Program
- Lung Force Walk
- Light the Bridge from Care to Cure Event – Human Cancer Ribbon
- Bone Marrow Drive Event
- Annual Celebration of Lights
- Tina's Treasures Sweet Spring Annual Event
- Nutrition/Colon Event
- Celebration of Life Annual Celebration
- Ladies Event for Women of Scottsdale, Central Phoenix Women, and East Valley Women
- Annual National Cancer Survivorship Day Celebration

Community Outreach Cancer Screenings Included:

- LPGA Golf Tournament Risk and Prevention Skin Screenings
- Skin Screening – Partnered with Center for Dermatology
- Breast Health Promotional Program and UV Facial Screening
- Annual Skin Cancer Screening and Ocular

Melanoma Screening
Annual Prostate
Screening

Community Outreach Educational Programs Included:

- MPBC Golf Classic – Anthem
- Decoding Annie Parker – Genetic Panel
- Desert Cancer Foundation Annual Learning Living with Cancer
- Be the Match Bone Marrow Donor Education
- Lymphedema Education Program
- Ladies’ Night Education Resources
- Smoking Cessation Classes
- Cancer Risk and Prevention
- The Transplant Experience
- An Insider’s Look at Stem Cell Transplant

Community Outreach Nutrition Programs Included:

- Eating For Life – Eat Real
- National Lymphoma Research Conference
- Nutrition Talk for Wellness Community
- Scottsdale Clinical Research Institute In-service for Staff
- Colorectal Survivorship Symposium
- Get Fit While You Sit
- Brighton Power of Pink
- Colon Cancer Alliance Group

Physician Committee Members	2014
Patrick Donovan	Medical Oncology
Timothy Kelsch	Otolaryngology
Luci Chen	Radiation Oncology
Sharon Gburek	Pathology
Mark Kuo	Radiology

Non-Physician Members	2014
Matt Schneider	Vice President
Selma Kendrick	Director- Oncology Service Line
Colleen McKeague	Medical Staff
Tom Bollard	Oncology Manager
Shanna Levy	Genetic Counseling
Gerrie Jakobs	Oncology Social Worker
Nancy McCutcheon	Community Outreach Manager
Melanie O’Hara	Care Coordinator
Marlene Miller	Care Coordinator
Terri Taylor	Nutrition Services
Terry Thomas	Cancer Registry
Molly Downhour	Clinical Trials
Kathy Manske	Palliative Care

2014 Osborn Cancer Conferences

There were 41 general tumor boards held at Osborn in 2014 with an average physician attendance of 11.0 per meeting and an average non-physician attendance of 3.1 per meeting.

There were 107 cases presented. Of them, 105 (98.1%) were prospective presentations.

There were an additional 71 tumor boards held at Shea in 2014 (42 general, 22 breast, 4 endocrine and 3 sarcoma). There were 292 cases

presented at Shea (178 general, 92 breast, 10 endocrine and 12 sarcoma). Of them 287 (98.3%) were prospective presentations.

Physician attendance at Shea tumor boards averaged 12.2; 12.3 at general, 13.3 at breast, 9.5 at endocrine and 7.7 at sarcoma.

Non-physician attendance at Shea tumor boards averaged 9.0; 9.9 at general, 9.0 at breast, 3.0 at endocrine and 4.7 at sarcoma.

Orbit	12	3%
Unknown	9	3%
Pancreas	8	2%
Total	290	81%

Note: Cervical carcinoma in situ, squamous or basal cell carcinomas of skin and intraepithelial neoplasias were excluded.

Among men, lung cancer was most prevalent; accounting for one 15.5% of all cancers accessioned.

Among women, breast cancer was the most prevalent; accounting for 31% of all cancers accessioned.

Ten Most Common Analytic Cancers Per Gender (2013 data)

Male Top Ten Sites	Incidence	Percentage Of Total Male Cases (n=271)
Lung	42	26%
Melanoma	29	11%
Lymphoma	27	10%
Colon	19	7%
Leukemia	14	5%
Kidney	12	4%
Sarcoma	10	4%
Brain	8	3%
Pancreas	8	3%
Rectum	8	3%
Total	177	76%
Female Top Ten Sites	Incidence	Percentage Of Total Female Cases (n=360)
Breast	112	31%
Lung	61	17%
Lymphoma	28	8%
Leukemia	18	5%
Thyroid	15	4%
Colon	14	4%
Meninges	13	4%

Analytic Cases Age by Gender (2013 data)

Age	Male	Female	Total
1-9	0	0	0
10-19	1	0	1
20-29	1	5	6
30-39	5	10	15
40-49	15	32	47
50-59	43	73	117
60-69	65	84	149
70-79	87	94	181
80-89	50	48	98
90-99	4	13	17
≥ 100	0	1	1
Total	271	360	631

Patients in their seventies accounted for 28.7% of all accessions in 2013. Patients in their fifties and in their seventies accounted for 18.5% and 23.6%, respectively. Collectively, patients of ages 50-79 accounted for 70.8% of all 2013 cases.

SCOTTSDALE HEALTHCARE OSBORN - 2011

Cancer Program Practice Profile Reports Summary for Breast, Colon and Rectal Cancers

Performance rates from the Commission on Cancer National Cancer Data Base for 2011 diagnoses comparison among SHC Osborn, SHC Osborn's upper limit of the 95% Confidence Interval, all Arizona accredited programs, and all CoC accredited programs.

The 95% Confidence Interval (C.I.) is a statistical tool for interpreting comparison data. In simplest terms, it means that there is a 95% chance that the true average value is contained within the specified range. The Commission on Cancer specifies that the upper limit of the 95% C.I. of a facility's measure should meet or exceed either the published standard's expected percentage or the actual percentage of all CoC accredited programs, collectively.

Breast Cancer Measures

Measure	SHC Osborn	SHC Osborn 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer	96.3%	100%	80.4%	92.7%
Combination chemotherapy is considered or administered within 4 months of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer	100%	100%	89.8%	93.1%
Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer	93.2%	100%	76.3%	91.7%

Colon Cancer Measures

Measure	SHC Osborn	SHC Osborn 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer	100%	100%	78.5%	91.7%
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer	100%	100%	86%	87.8%

Rectal Cancer Measure

Measure	SHC Osborn	SHC Osborn 95% C.I.	AZ Accredited Programs	CoC Accredited Programs
Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer	100%	100%	70.8%	92.7%

Additional Breast Measures for Surveillance and Quality Improvement (no required compliance value)

Measure	SHC Osborn	SHC Osborn 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer (Surveillance only)	55.8%	66.9%	55.8%	64.0%

Scottsdale Healthcare Osborn 2014 Cancer Program Annual Report

Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer (Quality Improvement only)	85.1%	93.2%	77.9%	83.2%
Radiation is considered or administered following any mastectomy within 1 year of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes (Surveillance only)	100%	100%	72.5%	79.1%

**PRIMARY SITE TABULATION
FOR 2013 SCOTTSDALE
HEALTHCARE SYSTEM**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
ALL SITES	2648	1223	1425	230	849	465	291	360	187	266
ORAL CAVITY	53	37	16	0	14	7	5	22	5	0
LIP	1	1	0	0	1	0	0	0	0	0
TONGUE	20	13	7	0	4	2	4	7	3	0
OROPHARYNX	2	1	1	0	0	0	0	2	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	30	22	8	0	9	5	1	13	2	0
DIGESTIVE SYSTEM	345	192	153	5	75	93	61	90	17	4
ESOPHAGUS	17	12	5	0	5	4	1	5	2	0
STOMACH	24	9	15	1	7	6	3	6	1	0
COLON	122	70	52	2	27	37	28	25	2	1
RECTUM	66	38	28	1	18	15	14	10	8	0
ANUS/ANAL CANAL	8	2	6	0	3	2	1	1	1	0
LIVER	16	10	6	0	8	0	1	7	0	0
PANCREAS	63	36	27	0	5	25	5	27	1	0
OTHER	29	15	14	1	2	4	8	9	2	3
RESPIRATORY SYSTEM	261	124	137	1	74	29	47	104	5	1
NASAL/SINUS	2	2	0	0	1	1	0	0	0	0
LARYNX	10	9	1	1	3	2	1	3	0	0
LUNG/BRONCHUS	246	111	135	0	69	26	46	99	5	1
OTHER	3	2	1	0	1	0	0	2	0	0
BLOOD & BONE MARROW	153	90	63	0	0	0	3	3	0	147
LEUKEMIA	82	46	36	0	0	0	3	3	0	76
MULTIPLE MYELOMA	39	21	18	0	0	0	0	0	0	39
OTHER	32	23	9	0	0	0	0	0	0	32

Scottsdale Healthcare Osborn 2014 Cancer Program Annual Report

BONE	10	4	6	0	4	2	0	0	4	0
CONNECT/SOFT TISSUE	44	31	13	0	11	8	15	5	4	1
SKIN	146	79	67	19	66	24	8	7	17	5
MELANOMA	138	76	62	19	63	22	8	7	16	3
OTHER	8	3	5	0	3	2	0	0	1	2
BREAST	457	4	453	95	195	103	30	13	21	0
FEMALE GENITAL	173	0	173	1	76	8	28	20	35	5
CERVIX UTERI	20	0	20	0	9	1	4	1	5	0
CORPUS UTERI	99	0	99	0	59	1	9	8	22	0
OVARY	35	0	35	0	5	2	14	8	6	0
VULVA	13	0	13	1	3	4	1	2	1	1
OTHER	6	0	6	0	0	0	0	1	1	4
MALE GENITAL	309	309	0	0	115	126	35	20	11	2
PROSTATE	299	299	0	0	112	125	34	20	8	0
TESTIS	8	8	0	0	3	1	1	0	2	1
OTHER	2	2	0	0	0	0	0	0	1	1
URINARY SYSTEM	276	204	72	109	76	31	16	21	21	2
BLADDER	166	130	36	103	18	26	8	9	2	0
KIDNEY/RENAL	96	69	27	1	53	5	8	10	19	0
OTHER	14	5	9	5	5	0	0	2	0	2
BRAIN & CNS	36	16	20	0	0	0	0	0	0	36
BRAIN (BENIGN)	1	1	0	0	0	0	0	0	0	1
BRAIN (MALIGNANT)	16	7	9	0	0	0	0	0	0	16
OTHER	19	8	11	0	0	0	0	0	0	19
ENDOCRINE	193	41	152	0	111	7	17	11	43	4
THYROID	189	40	149	0	111	7	17	11	43	0
OTHER	4	1	3	0	0	0	0	0	0	4
LYMPHATIC SYSTEM	123	61	62	0	31	25	18	42	2	5
HODGKIN'S DISEASE	12	4	8	0	2	6	1	3	0	0
NON-HODGKIN'S	111	57	54	0	29	19	17	39	2	5
UNKNOWN PRIMARY	46	23	23	0	0	0	0	0	0	46
OTHER/ILL-DEFINED	23	8	15	0	1	2	8	2	2	8

Number of cases excluded: 4
This report EXCLUDES CA in-situ
cervix cases, squamous and basal
cell skin cases,
and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION
FOR 2013-SHEA-ANALYTIC**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
ALL SITES	1680	807	873	182	566	320	173	179	118	142
ORAL CAVITY	30	16	14	0	9	4	2	13	2	0
LIP	1	1	0	0	1	0	0	0	0	0
TONGUE	10	4	6	0	2	1	1	5	1	0
OROPHARYNX	1	1	0	0	0	0	0	1	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	18	10	8	0	6	3	1	7	1	0
DIGESTIVE SYSTEM	191	102	89	2	44	51	36	48	7	3
ESOPHAGUS	10	7	3	0	3	2	1	4	0	0
STOMACH	16	6	10	1	4	5	1	4	1	0
COLON	65	37	28	0	18	17	16	12	2	0
RECTUM	33	18	15	1	11	9	6	4	2	0
ANUS/ANAL CANAL	5	2	3	0	2	1	0	1	1	0
LIVER	2	0	2	0	1	0	0	1	0	0
PANCREAS	42	22	20	0	3	15	5	18	1	0
OTHER	18	10	8	0	2	2	7	4	0	3
RESPIRATORY SYSTEM	120	58	62	0	39	13	21	45	2	0
NASAL/SINUS	1	1	0	0	0	1	0	0	0	0
LARYNX	3	2	1	0	1	2	0	0	0	0
LUNG/BRONCHUS	115	54	61	0	38	10	21	44	2	0
OTHER	1	1	0	0	0	0	0	1	0	0
BLOOD & BONE MARROW	107	65	42	0	0	0	1	1	0	105
LEUKEMIA	53	31	22	0	0	0	1	1	0	51
MULTIPLE MYELOMA	32	18	14	0	0	0	0	0	0	32
OTHER	22	16	6	0	0	0	0	0	0	22
BONE	8	2	6	0	2	2	0	0	4	0
CONNECT/SOFT TISSUE	27	19	8	0	8	7	6	4	2	0
SKIN	75	44	31	12	39	9	3	2	10	0
MELANOMA	73	43	30	12	38	9	3	2	9	0
OTHER	2	1	1	0	1	0	0	0	1	0

Scottsdale Healthcare Osborn 2014 Cancer Program Annual Report

BREAST	344	2	342	77	143	79	22	7	16	0
FEMALE GENITAL	51	0	51	0	20	3	6	7	12	3
CERVIX UTERI	2	0	2	0	0	0	0	0	2	0
CORPUS UTERI	30	0	30	0	18	1	2	2	7	0
OVARY	13	0	13	0	1	2	4	4	2	0
VULVA	1	0	1	0	1	0	0	0	0	0
OTHER	5	0	5	0	0	0	0	1	1	3
MALE GENITAL	261	261	0	0	93	111	31	14	10	2
PROSTATE	253	253	0	0	90	111	30	14	8	0
TESTIS	7	7	0	0	3	0	1	0	2	1
OTHER	1	1	0	0	0	0	0	0	0	1
URINARY SYSTEM	220	158	62	91	57	26	15	10	19	2
BLADDER	138	105	33	89	12	23	7	5	2	0
KIDNEY/RENAL	74	50	24	1	41	3	8	4	17	0
OTHER	8	3	5	1	4	0	0	1	0	2
BRAIN & CNS	4	3	1	0	0	0	0	0	0	4
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	1	0	1	0	0	0	0	0	0	1
OTHER	3	3	0	0	0	0	0	0	0	3
ENDOCRINE	158	33	125	0	96	5	16	6	33	2
THYROID	156	33	123	0	96	5	16	6	33	0
OTHER	2	0	2	0	0	0	0	0	0	2
LYMPHATIC SYSTEM	60	30	30	0	15	10	13	21	1	0
HODGKIN'S DISEASE	6	1	5	0	1	2	1	2	0	0
NON-HODGKIN'S	54	29	25	0	14	8	12	19	1	0
UNKNOWN PRIMARY	19	10	9	0	0	0	0	0	0	19
OTHER/ILL-DEFINED	5	4	1	0	1	0	1	1	0	2

Number of cases excluded: 0
 This report EXCLUDES CA in-situ
 cervix cases, squamous and basal
 cell skin cases, and
 intraepithelial neoplasia cases

**PRIMARY SITE TABULATION
FOR 2013 OSBORN**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
ALL SITES	613	272	341	33	161	95	59	129	38	98
ORAL CAVITY	19	18	1	0	4	3	3	6	3	0
LIP	0	0	0	0	0	0	0	0	0	0
TONGUE	9	8	1	0	1	1	3	2	2	0
OROPHARYNX	0	0	0	0	0	0	0	0	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	10	10	0	0	3	2	0	4	1	0
DIGESTIVE SYSTEM	100	62	38	3	20	24	15	30	8	0
ESOPHAGUS	6	4	2	0	2	1	0	1	2	0
STOMACH	5	2	3	0	2	0	2	1	0	0
COLON	34	21	13	2	4	11	7	10	0	0
RECTUM	19	13	6	0	3	3	4	5	4	0
ANUS/ANAL CANAL	3	0	3	0	1	1	1	0	0	0
LIVER	12	9	3	0	6	0	1	5	0	0
PANCREAS	15	10	5	0	2	8	0	5	0	0
OTHER	6	3	3	1	0	0	0	3	2	0
RESPIRATORY SYSTEM	110	50	60	1	27	14	17	49	1	1
NASAL/SINUS	1	1	0	0	1	0	0	0	0	0
LARYNX	6	6	0	1	2	0	1	2	0	0
LUNG/BRONCHUS	101	42	59	0	23	14	16	46	1	1
OTHER	2	1	1	0	1	0	0	1	0	0
BLOOD & BONE MARROW	33	15	18	0	0	0	1	1	0	31
LEUKEMIA	20	9	11	0	0	0	1	1	0	18
MULTIPLE MYELOMA	6	2	4	0	0	0	0	0	0	6
OTHER	7	4	3	0	0	0	0	0	0	7
BONE	2	2	0	0	2	0	0	0	0	0
CONNECT/SOFT TISSUE	13	11	2	0	1	1	7	1	2	1
SKIN	66	34	32	7	26	14	3	5	7	4
MELANOMA	61	32	29	7	25	12	3	5	7	2
OTHER	5	2	3	0	1	2	0	0	0	2
BREAST	102	2	100	17	49	22	7	5	2	0
FEMALE GENITAL	11	0	11	0	2	0	1	0	7	1
CERVIX UTERI	1	0	1	0	0	0	0	0	1	0
CORPUS UTERI	5	0	5	0	1	0	0	0	4	0

Scottsdale Healthcare Osborn 2014 Cancer Program Annual Report

OVARY	3	0	3	0	1	0	1	0	1	0
VULVA	1	0	1	0	0	0	0	0	1	0
OTHER	1	0	1	0	0	0	0	0	0	1
MALE GENITAL	5	5	0	0	0	0	0	5	0	0
PROSTATE	5	5	0	0	0	0	0	5	0	0
TESTIS	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0
URINARY SYSTEM	21	19	2	5	5	2	1	8	0	0
BLADDER	9	8	1	4	1	1	1	2	0	0
KIDNEY/RENAL	10	10	0	0	4	1	0	5	0	0
OTHER	2	1	1	1	0	0	0	1	0	0
BRAIN & CNS	32	13	19	0	0	0	0	0	0	32
BRAIN (BENIGN)	1	1	0	0	0	0	0	0	0	1
BRAIN (MALIGNANT)	15	7	8	0	0	0	0	0	0	15
OTHER	16	5	11	0	0	0	0	0	0	16
ENDOCRINE	23	6	17	0	10	0	1	3	7	2
THYROID	21	5	16	0	10	0	1	3	7	0
OTHER	2	1	1	0	0	0	0	0	0	2
LYMPHATIC SYSTEM	52	25	27	0	15	13	2	16	1	5
HODGKIN'S DISEASE	6	3	3	0	1	4	0	1	0	0
NON-HODGKIN'S	46	22	24	0	14	9	2	15	1	5
UNKNOWN PRIMARY	17	8	9	0	0	0	0	0	0	17
OTHER/ILL-DEFINED	7	2	5	0	0	2	1	0	0	4

Number of cases excluded: 1
 This report EXCLUDES CA in-situ
 cervix cases, squamous and basal
 cell skin cases,
 and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION
FOR 2013 TPK**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
ALL SITES	354	144	210	15	122	50	59	52	30	26
ORAL CAVITY	4	3	1	0	1	0	0	3	0	0
LIP	0	0	0	0	0	0	0	0	0	0
TONGUE	1	1	0	0	1	0	0	0	0	0
OROPHARYNX	1	0	1	0	0	0	0	1	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	2	2	0	0	0	0	0	2	0	0
DIGESTIVE SYSTEM	54	28	26	0	11	18	10	12	2	1
ESOPHAGUS	1	1	0	0	0	1	0	0	0	0
STOMACH	3	1	2	0	1	1	0	1	0	0
COLON	23	12	11	0	5	9	5	3	0	1
RECTUM	14	7	7	0	4	3	4	1	2	0
ANUS/ANAL CANAL	0	0	0	0	0	0	0	0	0	0
LIVER	2	1	1	0	1	0	0	1	0	0
PANCREAS	6	4	2	0	0	2	0	4	0	0
OTHER	5	2	3	0	0	2	1	2	0	0
RESPIRATORY SYSTEM	31	16	15	0	8	2	9	10	2	0
NASAL/SINUS	0	0	0	0	0	0	0	0	0	0
LARYNX	1	1	0	0	0	0	0	1	0	0
LUNG/BRONCHUS	30	15	15	0	8	2	9	9	2	0
OTHER	0	0	0	0	0	0	0	0	0	0
BLOOD & BONE MARROW	13	10	3	0	0	0	1	1	0	11
LEUKEMIA	9	6	3	0	0	0	1	1	0	7
MULTIPLE MYELOMA	1	1	0	0	0	0	0	0	0	1
OTHER	3	3	0	0	0	0	0	0	0	3
BONE	0	0	0	0	0	0	0	0	0	0
CONNECT/SOFT TISSUE	4	1	3	0	2	0	2	0	0	0
SKIN	5	1	4	0	1	1	2	0	0	1
MELANOMA	4	1	3	0	0	1	2	0	0	1
OTHER	1	0	1	0	1	0	0	0	0	0
BREAST	10	0	10	1	3	2	1	1	2	0
FEMALE GENITAL	111	0	111	1	54	5	21	13	16	1
CERVIX UTERI	17	0	17	0	9	1	4	1	2	0
CORPUS UTERI	64	0	64	0	40	0	7	6	11	0
OVARY	19	0	19	0	3	0	9	4	3	0

Scottsdale Healthcare Osborn 2014 Cancer Program Annual Report

VULVA	11	0	11	1	2	4	1	2	0	1
OTHER	0	0	0	0	0	0	0	0	0	0
MALE GENITAL	43	43	0	0	22	15	4	1	1	0
PROSTATE	41	41	0	0	22	14	4	1	0	0
TESTIS	1	1	0	0	0	1	0	0	0	0
OTHER	1	1	0	0	0	0	0	0	1	0
URINARY SYSTEM	35	27	8	13	14	3	0	3	2	0
BLADDER	19	17	2	10	5	2	0	2	0	0
KIDNEY/RENAL	12	9	3	0	8	1	0	1	2	0
OTHER	4	1	3	3	1	0	0	0	0	0
BRAIN & CNS	0	0	0	0	0	0	0	0	0	0
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0
ENDOCRINE	12	2	10	0	5	2	0	2	3	0
THYROID	12	2	10	0	5	2	0	2	3	0
OTHER	0	0	0	0	0	0	0	0	0	0
LYMPHATIC SYSTEM	11	6	5	0	1	2	3	5	0	0
HODGKIN'S DISEASE	0	0	0	0	0	0	0	0	0	0
NON-HODGKIN'S	11	6	5	0	1	2	3	5	0	0
UNKNOWN PRIMARY	10	5	5	0	0	0	0	0	0	10
OTHER/ILL-DEFINED	11	2	9	0	0	0	6	1	2	2

Number of cases excluded: 0
 This report EXCLUDES CA in-situ
 cervix cases, squamous and basal
 cell skin cases,
 and intraepithelial neoplasia cases